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Summary
 Background: Thermal ablation procedures, including radiofrequency ablation (RFA) or laser-induced intersti-
tial thermotherapy (LITT), are now well established in the treatment of malignant unresectable 
hepatic tumors. But the impact of partial ablation (PA) on long-term survival following comput-
ed tomography (CT)-guided radiofrequency ablation and laser- induced interstitial thermother-
apy of unresectable malignant liver lesions and the associated risk factors of PA remain partially 
unknown.
 Material/Methods: This study included 254 liver tumors in 91 consecutive patients (66 men and 25 women; age 60.9±10.4 
years; mean tumor size 25±14 mm [range 5–70 mm]) who underwent thermal ablation (RFA or 
LITT) between January 2000 and December 2007. Mean follow-up period was 21.1 month (range 
1–69 months). Survival rate and local progression-free survival (PFS) were calculated for patients 
with complete ablation (CA) vs. patients with partial ablation (PA) to assess the impact on long-
term survival.
 Results: Median survival after CA was 47 months compared to 25 months after PA (P=0.04). The corre-
sponding 5-year survival rates were 44% vs. 20%. Median PFS for CA was 11 months compared to 
7 months for PA (P=0.118). The sole statistically significant risk factor for PA was tumor size (>30 
mm; P=0.0003). Sustained complete ablation was achieved in 71% of lesions ≤30 mm vs. 47% of 
lesions >30 mm.
 Conclusions: We conclude that achievement of complete ablation is a highly important predictor of long-term 
survival and that tumor size is by far the most important predictor of the likelihood of achieving 
complete ablation.
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Background
Thermal ablation procedures, including radiofrequency 
ablation (RFA) or laser-induced interstitial thermothera-
py (LITT), are now well established in the treatment of ma-
lignant unresectable hepatic tumors. This includes prima-
ry malignant liver tumors such as hepatocellular carcinoma 
(HCC) as well as metastases, especially from colorectal can-
cer (CRC) [1–6]. The main objective of thermal ablation is 
to induce in situ coagulation necrosis for complete destruc-
tion of targeted tumors with only limited damage to the sur-
rounding normal tissues. Compared to other in situ ablation 
techniques such as microwave, cryoablation, high-intensity 
focused ultrasound (HIFU), and percutaneous ethanol in-
jection (PEI), RFA and LITT seem to be the best options 
as both of them produce a comparatively large coagulation 
necrosis and are associated with a low rate of complications 
[7]. In RFA, a shielded needle electrode is inserted directly 
to the tumor under image guidance. The RF energy heats 
tissue by applying alternating current, resulting in ionic agi-
tation. This local temperature rise induces a necrotic lesion 
around the needle tip. Similarly, in LITT laser light is direct-
ly transmitted percutaneously through flexible bare fibers 
into the tumor tissue. The biologic effect of the laser light 
is based on the absorption of laser photon energy by the tis-
sue, leading to a local temperature rise. The aim is to induce 
coagulation necrosis of the treatment volume.Tumors in a 
variety of organs, including the lungs and kidneys [2,8–12] 
have been treated with thermal ablation, but thus far the liv-
er has been the organ of primary interest. This is because 
thermal ablation of malignant liver lesions is a potentially 
curative treatment, it is less invasive, and it results in few-
er complications compared with surgery [13–15]. Thermal 
ablation has shown promising results in local tumor con-
trol [14,16,17], but only when a complete thermal coagula-
tion of the tumor, with no viable tumor cells in the treated 
area, is achieved. However, partial ablation of liver tumors 
is achieved in up to 52% of cases [18–21]. The purpose of 
this study was to assess the impact of partial ablation on the 
long-term survival of patients with malignant liver lesions.
Material and Methods
Patients and indications for thermal ablation
This retrospective study reviewed 91 consecutive patients 
with a total of 254 primary or secondary hepatic malignan-
cies treated by thermal ablation (RFA: n=79, LITT: n= 12) 
between January 2000 and December 2007 (Table 1). All pa-
tients were referred from a multidisciplinary team. The indi-
cations for thermal ablation were extensively discussed at the 
visceral tumor board and only patients not eligible for liver 
resection underwent ablation. The exclusion criteria for RFA 
were as follows: eligibility for liver resection, presence of more 
than 5 intrahepatic nodules, a maximum tumor size of more 
than 7 cm, and extrahepatic disease. The procedures for ther-
mal ablation of malignant liver lesions have been previous-
ly described in detail [22,23]. All ablations were performed 
percutaneously under analgo-sedation, and by CT guidance.
Postoperative evaluation and follow-up
All patients underwent a CT scan at 4–6 weeks after abla-
tion to assess and evaluate the results of the procedure, at 
4, 8, and 12 months following the thermal ablation treat-
ment, and subsequently every 6 months. Complete ablation 
(CA) was defined as complete necrosis of all malignant liver 
lesions, without any contrast enhancement at any phase of 
the exploration and no recurrent disease within a 10 mm 
margin of the ablated regions during the follow-up period. 
Partial ablation (PA) was defined as the persistence of vas-
cular enhancement peripheral to or at the treatment site 
at the first follow-up scan, or recurrent disease within a 10 
mm margin during follow-up.
Statistical analysis
All data were statistically analyzed by using Microsoft Excel 
(Microsoft, Inc., Redmond, WA) and SPSS (SPSS for 
Windows, version 17, SPSS Inc., Chicago, Illinois). We ap-
plied a cut-off for continuous-type variables (e.g., size or age) 
to convert them to an ordinal scale corresponding to cat-
egories used in the literature. Univariate analysis was used 
to describe differences among groups defined according to 
the characteristics mentioned above. Chi-square or Fisher’s 
exact tests were used to compare the proportions for qual-
itative variables. Overall survival from the time of the first 
thermal ablation treatment to the death of the patient or 
end of observation was calculated for all patients using the 
Kaplan-Meier method. Difference among groups was deter-
mined by the log-rank test. A value of P<0.05 was consid-
ered statistically significant. All data are expressed as mean 
±SD or median + range.
results
A total of 91 patients with liver malignancies underwent ther-
mal ablation during the study period (Table 1). There were 
66 men (73%) and 25 women (27%) with a mean age of 60.9 
years (±10.4 years). Eighty-three (91.2%) patients had meta-
static liver malignancies, of which 54 were colorectal liver me-
tastases (65%), and 8 (8.8%) patients had HCC. The median 
number of tumors per patient was 3 (range 1–5). A total of 
Characteristics
No. of tumors
(no. of patients)
or mean ± SD
Gender Male (66)
Female (25)
Age (years) 60.92±10.39
Tumor size (cm) 2.54±1.40
No. of lesions 2.79±1.45
Tumor type
 HCC 18 (8)
 Metastatic liver
 malignancies 236 (83)
Colorectal cancer (54)
Other (29)
Table 1.  Characteristics of 254 liver tumors in patient characteristics.
254 tumors were treated in these 91 patients. Among these 
tumors, 236 (92.9%) were liver metastases and 18 (7.1%) 
were hepatic primary (HCC). Thermal ablation was used to 
treat a single tumor in 24.2% of cases. Two tumors in 24.2% 
of cases. Three nodules were treated during the same proce-
dure in 18.7% of cases, 4 nodules in 14.3%, and 5 nodules 
were treated in 18.7% of cases. Mean size of the ablated tu-
mor was 25 mm in diameter (range 5–70 mm). Treatment 
with thermal ablation, always performed under CT guid-
ance, was technically feasible in all cases. Thirty-day mortal-
ity was 0%, with no deaths related to postprocedural compli-
cations or morbidity. Median follow-up time from ablation 
until death or end of observation was 19 months (mean, 
21.1 months), with a range of 1 to 69 months.
Survival
The estimated median survival for all patients who had ther-
mal ablation of their malignant liver lesions was 29 months 
(95% CI 18–40 month). The estimated median survival for 
patients who had a complete ablation or a partial ablation 
was 47 months (95% CI 17.9–76.0 month) and 25 months 
(18.1–31.9 months), respectively. The 5-year overall survival 
after a complete ablation was 44%, while the 5-year survival 
after a partial ablation was 20%, as shown in Figure 1. This 
difference was statistically significant (P=0.041).
Progression-free survival (PFS)
The median time to progression of disease for patients who 
had a PA was 7 months (95% CI: 4.46–9.54 months), com-
pared to 11 months (95% CI: 4.23–17.77 month) for pa-
tients with a CA (P=0.118). The corresponding mean time 
to progression was 9.81±1.34 months for partial ablations 
and 16.05±2.76 months for a complete ablation (Figure 2). 
Complete tumor ablation was achieved in 96% of cases at 
the first follow-up CT scan (at 4–6 weeks). The long-term 
complete ablation figure was 62% after a mean follow-up 
of 21.1 months (range 1–69).
Determinants of partial ablation
Based on these significant differences in survival times for 
complete and partial ablation, we analyzed potential vari-
ables that could have an impact on partial ablation of tumors 
(Table 2). The following variables were analyzed: sex, tumor 
size (>30 mm vs. ≤30 mm), tumor histopathology (HCC vs. 
liver metastases) and patient age (>70 years vs. ≤70 years). 
Of 254 lesions that were evaluated during follow-up, com-
plete and sustained ablation was achieved in 96% of cases 
by the first follow-up CT scan (at 4–6 weeks). The sex, age, 
tumor type and number of lesions of patients with residu-
al tumor or recurrence of disease were not statistically dif-
ferent from those of patients with a complete ablation of 
the treated lesions. Only lesion size had a statistically sig-
nificant impact on the risk of residual tumor or recurrence 
(p=0.0003). The complete ablation rate for tumors ≤30 mm 
was 71% compared to 47% for lesions larger than 30 mm.
discussion
Surgical resection is currently the only therapeutic option 
with a potential curative effect for patients with liver me-
tastases. However, in more than 70% of cases the surgical 
approach is contraindicated due to poor liver reserve, in-
sufficient health status, or an overly advanced tumor stage 
[18,24–28]. For this reason, there is a need for alternative 
treatment options for patients with unresectable liver ma-
lignancies [29–31]. Thermal ablation techniques, such as 
RFA and LITT, have gained a high degree of acceptance and 
are the therapeutic option of choice in the treatment of un-
resectable liver malignancies [32–35]. The main objective 
of thermal ablation of malignant liver tumors is to achieve 
a complete thermal coagulation of the tumor, thus leaving 
no viable tumor cells in the treated area. Nevertheless, par-
tial ablation or recurrent disease is a frequent problem in 
thermal ablation procedures, where rates of up to 52% have 
been cited [18,21]. In our retrospective study the rate of 
Figure 1.  Cumulative survival curves for complete and partial ablation 
calculated by the Kaplan-Meier method.
Figure 2.  Time to local progress for patients with complete or partial 
ablation. Median time to progression for PA was 7 months, 
compared to 11 months for patients with a CA.
local recurrence was 38%, which is in line with the reported 
figures. Even though there are many available case series in 
the literature on thermal ablation, there is only limited data 
on recurrence risk factors [36], predictive factors for surviv-
al, and on long-term results [37–39]. The interim results of 
the only prospective randomized phase II study (CLOCC 
trial [chemotherapy plus local ablation vs. chemotherapy]) 
initiated by the European Organization for Research and 
Treatment of Cancer could not demonstrate a statically sig-
nificant impact of RFA plus chemotherapy compared to 
chemotherapy alone for patients with an advanced stage of 
unresectable metastatic colorectal cancer liver disease [40]. 
The 30-month overall survival rates were 64.9% (95% CI, 
51.13–77.09) for RFA plus chemotherapy and 56.9% (95% 
CI 43.23–69.84) for chemotherapy alone. There was, howev-
er, a significant trend in the prolongation of progression-free 
survival for patients who were treated with RFA (p=0.025). 
No prospective trial comparing RFA to surgical resection in 
patients with similar extent of liver metastases has been con-
ducted to date. However, the better survival of patients with 
CA when compared to patients with PA might indicate the 
effectiveness of local thermo- therapies. This study aimed to 
identify predictive factors for effective percutaneous ther-
mal ablation and evaluate the impact of complete ablation 
on overall survival. As has been reported before by Ayav et 
al. [41], our study reiterates that tumor size is a significant 
factor associated with partial ablation or local recurrence. 
For tumors larger than 30 mm the local recurrence was 53% 
(49 of 93 tumors >30 mm). However, for tumors smaller or 
equal to 30 mm the respective number was 29% (48 of 161 
tumors ≤30 mm). Lam et al. [42] reported that the median 
age of patients with local recurrence after RFA was 66 vs. 60 
for patients without local recurrence (p=0.05). We did not 
observe this trend in our study. As previously reported, we 
confirmed that tumor pathology had no influence on par-
tial ablation or local recurrence [43,44]. Age and sex where 
also not significant predictors of partial ablation. In order 
to evaluate the therapeutic impact of complete ablation we 
analyzed its impact on long-term survival. For patients with 
a partial ablation, median survival was 25 months and the 
5-year survival was 20%. However, for patients with a com-
plete ablation, median survival was 47 months and the 5-year 
survival was 44%, comparable to similar survival rates follow-
ing surgical resection which have been widely reported in 
the literature [45,46]. This result, showing better local suc-
cess in smaller lesions, might indicate that the concept of 
a safety margin is not only useful in the surgical approach 
but also for thermal ablation. According to these findings, 
we now caution against the use of thermal ablation for tu-
mors >30 mm. Our retrospective study has certain limita-
tions, such as the nonuniform histopathologic types of liver 
tumors (i.e. HCC and metastatic liver tumor from various 
organs) as well as the small number of patients evaluated.
conclusions
Thermal ablation has proved to be an effective treatment 
option for local control of small, unresectable hepatic ma-
lignancies. We demonstrated with statistical significance 
that achievement of complete ablation is a highly impor-
tant predictor of long-term survival and that tumor size is 
by far the most important predictor of achieving complete 
ablation. We conclude that lesions of less than or equal to 
30 mm have a higher probability of achieving a complete 
ablation and are thus recommendable candidates for ther-
mal ablation techniques.
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